AKTS
NASDAQ HealthcareAktis Oncology, Inc. - Common stock
Biotechnology
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $20.25 |
|---|---|
| 成交量 | 205,250 |
| 市值 | 1.12B |
| RSI（14日） | 74.6 超买 |
| 50日均线 | $18.45 |
| 52周最高 | $29.16 |
| 52周最低 | $14.72 |
| Forward P/E | -12.17 |
| Price / Book | -0.13 |
🎯 投资策略评分
AKTS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (56/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (6/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 AKTS in your text
粘贴任何文章、记录或帖子 — 工具将提取 AKTS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.